Gallia G. Levy

7.0k total citations · 5 hit papers
41 papers, 4.6k citations indexed

About

Gallia G. Levy is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Gallia G. Levy has authored 41 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 17 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Gallia G. Levy's work include Hemophilia Treatment and Research (26 papers), Platelet Disorders and Treatments (15 papers) and Blood Coagulation and Thrombosis Mechanisms (12 papers). Gallia G. Levy is often cited by papers focused on Hemophilia Treatment and Research (26 papers), Platelet Disorders and Treatments (15 papers) and Blood Coagulation and Thrombosis Mechanisms (12 papers). Gallia G. Levy collaborates with scholars based in United States, Switzerland and Japan. Gallia G. Levy's co-authors include Midori Shima, Christophe Schmitt, Johannes Oldenburg, Johnny Mahlangu, Rebecca Kruse‐Jarres, Michael U. Callaghan, Elina Asikanius, Guy Young, Claude Négrier and Víctor Jiménez‐Yuste and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Gallia G. Levy

41 papers receiving 4.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

2001 1.3k citations Gallia G. Levy, William C. Nichols et al. Nature profile →
Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. New England Journal of Medicine profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. New England Journal of Medicine profile →
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Steven W. Pipe, Midori Shima et al. The Lancet Haematology profile →
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

2019 263 citations Guy Young, Ri Liesner et al. Blood profile →

Peers

Countries citing papers authored by Gallia G. Levy

Since Specialization

Citations

This map shows the geographic impact of Gallia G. Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gallia G. Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gallia G. Levy more than expected).

Fields of papers citing papers by Gallia G. Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gallia G. Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gallia G. Levy. The network helps show where Gallia G. Levy may publish in the future.

Co-authorship network of co-authors of Gallia G. Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Gallia G. Levy. A scholar is included among the top collaborators of Gallia G. Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gallia G. Levy. Gallia G. Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 2022 ·Research and Practice in Thrombosis and Haemostasis ·Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter C. Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi	7
2	Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011 2022 ·Blood ·Stacy E. Croteau, M. Elaine Eyster, Huyen Tran, Margaret V. Ragni, Benjamin J. Samelson‐Jones, Lindsey A. George, Spencer K. Sullivan, John E.J. Rasko, Jill Moormeier, Pantep Angchaisuksiri, Jerome Teitel, Gili Kenet, Tung Wynn, (unknown), Amy MacDougall, (unknown), Trupti Trivedi, Federico Mingozzi, Tiffany Chang, Gallia G. Levy	5
3	Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study 2022 ·Haemophilia ·Anna Kiialainen, Markus Niggli, Christine L. Kempton, Giancarlo Castaman, Tiffany Chang, Ido Paz‐Priel, Joanne I. Adamkewicz, Gallia G. Levy	23
4	The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 2021 ·Haemophilia ·Mark W. Skinner, Claude Négrier, Ido Paz‐Priel, Sammy Chebon, Víctor Jiménez‐Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapiro, Midori Shima, Avrita Campinha‐Bacote, Gallia G. Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W. Pipe	34
5	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies 2020 ·Blood ·Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg	170
6	Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) 2020 ·Blood ·Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg	4
7	Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study 2020 ·Pediatric Blood & Cancer ·Johannes Oldenburg, Midori Shima, Rebecca Kruse‐Jarres, Elena Santagostino, Johnny Mahlangu, Michaela Lehle, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Peter C. Trask, Maria Elisa Mancuso, Víctor Jiménez‐Yuste, Sylvia von Mackensen, Gallia G. Levy	12
8	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study 2019 ·Hämostaseologie ·Johannes Oldenburg, Johnny Mahlangu, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres	2
9	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study breakdown → 2019 ·The Lancet Haematology ·Steven W. Pipe, Midori Shima, Michaela Lehle, Amy D. Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S. Key, Agnès Portron, Christophe Schmitt, Maria Podolak‐Dawidziak, Nives Selak Bienz, Cédric Hermans, Avrita Campinha‐Bacote, Anna Kiialainen, Kathelijne Peerlinck, Gallia G. Levy, Víctor Jiménez‐Yuste	273
10	Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting 2017 ·Blood ·Johannes Oldenburg, Midori Shima, Rebecca Kruse‐Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy	2
11	Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study 2017 ·Blood ·Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse‐Jarres, Christine L. Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, Guy Young, Johannes Oldenburg	14
12	Emicizumab Prophylaxis in Hemophilia A with Inhibitors breakdown → 2017 ·New England Journal of Medicine ·Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U. Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse‐Jarres, Claude Négrier, Craig M. Kessler, Nancy Valente, Elina Asikanius, Gallia G. Levy, Jerzy Windyga, Midori Shima	759
13	HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors 2017 ·Blood ·Guy Young, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Gallia G. Levy, Midori Shima, Johnny Mahlangu	43
14	Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4) 2017 ·Blood ·Víctor Jiménez‐Yuste, Midori Shima, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron, Gallia G. Levy	16
15	ANNEXATM-R: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, DEMONSTRATING REVERSAL OF RIVAROXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS 2015 ·Journal of the American College of Cardiology ·(unknown), Mark Crowther, Gallia G. Levy, Genmin Lu, Janet M. Leeds, (unknown), Pamela B. Conley, Janice Castillo, John T. Curnutte, Stuart J. Connolly	22
16	The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele 2008 ·Mammalian Genome ·Jill M. Johnsen, Gallia G. Levy, Randal J. Westrick, Priscilla K. Tucker, David Ginsburg	19
17	ADAMTS13 turns 3 2005 ·Blood ·Gallia G. Levy, David G. Motto, David Ginsburg	96
18	Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura breakdown → 2001 ·Nature ·Gallia G. Levy, William C. Nichols, Eric C.‐Y. Lian, Tatiana Foroud, Jeanette N. McClintick, Beth McGee, Angela Yang, David Siemieniak, (unknown), Ralph A. Gruppo, Ravi Sarode, Susan B. Shurin, Visalam Chandrasekaran, Sally P. Stabler, Hernan Sabio, Eric E. Bouhassira, Jefferson D. Upshaw, David Ginsburg, Han‐Mou Tsai	1254
19	Cloning and Characterization of zRICH, a 2′,3′‐Cyclic‐Nucleotide 3′‐Phosphodiesterase Induced During Zebrafish Optic Nerve Regeneration 1999 ·Journal of Neurochemistry ·Rafael P. Ballestero, (unknown), Gallia G. Levy, Bernard W. Agranoff, Michael D. Uhler	29
20	The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA gene 1997 ·Nature Genetics ·Dominique Weil, (unknown), Stéphane Blanchard, Gallia G. Levy, Fabienne Lévi-Acobas, Mohamed Drira, Hammadi Ayadi, Christine Petit	313

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact